ROYALTY PHARMA PLC- CL A (RPRX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:RPRX • GB00BMVP7Y09

43.68 USD
+0.71 (+1.65%)
At close: Feb 4, 2026
43.68 USD
0 (0%)
After Hours: 2/4/2026, 8:00:03 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to RPRX. RPRX was compared to 191 industry peers in the Pharmaceuticals industry. While RPRX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on RPRX.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year RPRX was profitable.
  • In the past year RPRX had a positive cash flow from operations.
  • RPRX had positive earnings in each of the past 5 years.
  • Each year in the past 5 years RPRX had a positive operating cash flow.
RPRX Yearly Net Income VS EBIT VS OCF VS FCFRPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

1.2 Ratios

  • The Return On Assets of RPRX (3.95%) is better than 84.82% of its industry peers.
  • The Return On Equity of RPRX (11.93%) is better than 85.86% of its industry peers.
  • The Return On Invested Capital of RPRX (6.43%) is better than 84.29% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for RPRX is significantly below the industry average of 12.83%.
  • The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(6.43%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.95%
ROE 11.93%
ROIC 6.43%
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
RPRX Yearly ROA, ROE, ROICRPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • The Profit Margin of RPRX (32.55%) is better than 95.29% of its industry peers.
  • In the last couple of years the Profit Margin of RPRX has declined.
  • Looking at the Operating Margin, with a value of 65.22%, RPRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Operating Margin of RPRX has declined.
Industry RankSector Rank
OM 65.22%
PM (TTM) 32.55%
GM N/A
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
RPRX Yearly Profit, Operating, Gross MarginsRPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 50 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • RPRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • RPRX has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, RPRX has more shares outstanding
  • The debt/assets ratio for RPRX is higher compared to a year ago.
RPRX Yearly Shares OutstandingRPRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
RPRX Yearly Total Debt VS Total AssetsRPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • Based on the Altman-Z score of 1.80, we must say that RPRX is in the distress zone and has some risk of bankruptcy.
  • RPRX has a Altman-Z score (1.80) which is comparable to the rest of the industry.
  • RPRX has a debt to FCF ratio of 9.47. This is a negative value and a sign of low solvency as RPRX would need 9.47 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 9.47, RPRX is in the better half of the industry, outperforming 79.58% of the companies in the same industry.
  • A Debt/Equity ratio of 1.34 is on the high side and indicates that RPRX has dependencies on debt financing.
  • With a Debt to Equity ratio value of 1.34, RPRX is not doing good in the industry: 75.92% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF 9.47
Altman-Z 1.8
ROIC/WACC0.73
WACC8.77%
RPRX Yearly LT Debt VS Equity VS FCFRPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 3.48 indicates that RPRX has no problem at all paying its short term obligations.
  • RPRX has a Current ratio of 3.48. This is comparable to the rest of the industry: RPRX outperforms 54.97% of its industry peers.
  • A Quick Ratio of 3.48 indicates that RPRX has no problem at all paying its short term obligations.
  • RPRX has a Quick ratio (3.48) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.48
Quick Ratio 3.48
RPRX Yearly Current Assets VS Current LiabilitesRPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • RPRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.24%.
  • The earnings per share for RPRX have been decreasing by -18.23% on average. This is quite bad
  • RPRX shows a small growth in Revenue. In the last year, the Revenue has grown by 3.70%.
  • Measured over the past years, RPRX shows a small growth in Revenue. The Revenue has been growing by 4.52% on average per year.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.53% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 10.65% on average over the next years. This is quite good.
EPS Next Y17.31%
EPS Next 2Y12.49%
EPS Next 3Y13.48%
EPS Next 5Y10.53%
Revenue Next Year17.2%
Revenue Next 2Y9.47%
Revenue Next 3Y8.62%
Revenue Next 5Y10.65%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RPRX Yearly Revenue VS EstimatesRPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
RPRX Yearly EPS VS EstimatesRPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 10.63, the valuation of RPRX can be described as very reasonable.
  • Based on the Price/Earnings ratio, RPRX is valued cheaper than 90.05% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of RPRX to the average of the S&P500 Index (28.25), we can say RPRX is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 8.42, the valuation of RPRX can be described as very reasonable.
  • Based on the Price/Forward Earnings ratio, RPRX is valued cheaply inside the industry as 91.62% of the companies are valued more expensively.
  • RPRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.50.
Industry RankSector Rank
PE 10.63
Fwd PE 8.42
RPRX Price Earnings VS Forward Price EarningsRPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • RPRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. RPRX is cheaper than 82.20% of the companies in the same industry.
Industry RankSector Rank
P/FCF 26.69
EV/EBITDA N/A
RPRX Per share dataRPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • RPRX has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as RPRX's earnings are expected to grow with 13.48% in the coming years.
PEG (NY)0.61
PEG (5Y)N/A
EPS Next 2Y12.49%
EPS Next 3Y13.48%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • RPRX has a Yearly Dividend Yield of 2.30%. Purely for dividend investing, there may be better candidates out there.
  • RPRX's Dividend Yield is rather good when compared to the industry average which is at 0.62. RPRX pays more dividend than 93.19% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, RPRX pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 2.3%

5.2 History

  • RPRX has been paying a dividend for over 5 years, so it has already some track record.
  • RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
RPRX Yearly Dividends per shareRPRX Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • RPRX pays out 49.36% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y12.49%
EPS Next 3Y13.48%
RPRX Yearly Income VS Free CF VS DividendRPRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B
RPRX Dividend Payout.RPRX Dividend Payout, showing the Payout Ratio.RPRX Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ROYALTY PHARMA PLC- CL A

NASDAQ:RPRX (2/4/2026, 8:00:03 PM)

After market: 43.68 0 (0%)

43.68

+0.71 (+1.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)02-11
Inst Owners81.5%
Inst Owner Change-1.67%
Ins Owners1.56%
Ins Owner Change6.8%
Market Cap25.21B
Revenue(TTM)2.35B
Net Income(TTM)764.96M
Analysts84.29
Price Target46.34 (6.09%)
Short Float %7.09%
Short Ratio6.84
Dividend
Industry RankSector Rank
Dividend Yield 2.3%
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)0%
PT rev (3m)4.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.79%
EPS NY rev (1m)0%
EPS NY rev (3m)5.1%
Revenue NQ rev (1m)-0.89%
Revenue NQ rev (3m)3.65%
Revenue NY rev (1m)0.83%
Revenue NY rev (3m)2.75%
Valuation
Industry RankSector Rank
PE 10.63
Fwd PE 8.42
P/S 10.73
P/FCF 26.69
P/OCF 10.48
P/B 3.93
P/tB 4.59
EV/EBITDA N/A
EPS(TTM)4.11
EY9.41%
EPS(NY)5.19
Fwd EY11.88%
FCF(TTM)1.64
FCFY3.75%
OCF(TTM)4.17
OCFY9.54%
SpS4.07
BVpS11.11
TBVpS9.51
PEG (NY)0.61
PEG (5Y)N/A
Graham Number32.06
Profitability
Industry RankSector Rank
ROA 3.95%
ROE 11.93%
ROCE 8.15%
ROIC 6.43%
ROICexc 7.12%
ROICexgc 7.53%
OM 65.22%
PM (TTM) 32.55%
GM N/A
FCFM 40.2%
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF 9.47
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 62.15%
Interest Coverage -5.67
Cash Conversion N/A
Profit Quality 123.5%
Current Ratio 3.48
Quick Ratio 3.48
Altman-Z 1.8
F-Score5
WACC8.77%
ROIC/WACC0.73
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
EPS Next Y17.31%
EPS Next 2Y12.49%
EPS Next 3Y13.48%
EPS Next 5Y10.53%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
Revenue Next Year17.2%
Revenue Next 2Y9.47%
Revenue Next 3Y8.62%
Revenue Next 5Y10.65%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year30.98%
EBIT Next 3Y14.48%
EBIT Next 5Y13.68%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%

ROYALTY PHARMA PLC- CL A / RPRX FAQ

Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?

ChartMill assigns a fundamental rating of 6 / 10 to RPRX.


What is the valuation status for RPRX stock?

ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.


How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?

ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for RPRX stock?

The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 10.63 and the Price/Book (PB) ratio is 3.93.


Can you provide the dividend sustainability for RPRX stock?

The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 5 / 10 and the dividend payout ratio is 49.36%.